Shin Nippon Biomedical Laboratories, Ltd. (YB3.F)
| Previous Close | 7.95 |
| Open | 8.15 |
| Bid | 0.00 x 43300 |
| Ask | 0.00 x 40900 |
| Day's Range | 8.15 - 8.15 |
| 52 Week Range | 8.15 - 15.60 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 348.814M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 10.19 |
| EPS (TTM) | 0.80 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 0.30 (3.65%) |
| Ex-Dividend Date | Sept 27, 2024 |
| 1y Target Est | N/A |
GlobeNewswireSatsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase3 Double-Blind, Randomized, Placebo-Controlled SUMMIT StudyDURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acut
- GlobeNewswire
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds without need for involved administration procedures and to rapidly achieve high drug plasma lev
